ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Kazia Therapeutics Limited (KZIA) stock surged +11.65%, trading at $3.45 on NASDAQ, up from the previous close of $3.09. The stock opened at $3.00, fluctuating between $3.00 and $3.58 in the recent session.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Employees | 9 |
Beta | 2.29 |
Sales or Revenue | $2.31M |
5Y Sales Change% | -0.988% |
Fiscal Year Ends | June |
Sector | Healthcare |
Industry | Biotechnology |